| 证券代码 | IPXL.O |
| 证券名称 | Impax Laboratories Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | - |
| 发行方式 | - |
| 首发上市日 | 1995-12-18 |
| 首发价格(元) | - |
| 首发数量(股) | 0 |
| 首发募资额(元) | - |
| 首发主承销商 | - |
| 货币单位 | USD |
| 公司名称 | Impax Laboratories, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 30831 Huntwood Avenue, Hayward, California, USA |
| 成立日期 | 1995 |
| 董事会主席 | Paul M. Bisaro |
| 公司属地 | United States 美国 |
| 公司网址 | www.impaxlabs.com |
| 电话 | +1 (510) 476-2000 |
| 传真 | +1 (510) 471-3200 |
| 公司简介 | Impax Laboratories, Inc. is a technology-based specialty pharmaceutical company utilizing their core competency in drug delivery and formulation expertise. They have a balanced business model consisting of a successful generic business targeting high-value solid oral and alternative dosage form Abbreviated New Drug Applications (ANDA), and a branded business currently focused on internally developing Central Nervous System (CNS) products where they can deliver meaningful patient benefits and develop strong intellectual property positions. |